Senexin C (2.5 mg/kg, i.v.; 100 mg/kg, p.o.) shows good oral bioavailability[1].
Senexin C (40 mg/kg; p.o.; twice daily for 4 weeks) suppresses the systemic growth of MV4-11 AML with good tolerability[1].
Pharmacokinetic Parameters of Senexin C in eight-week-old female Balb/c mice[1].
| parameters | iv (2.5 mg/kg) | po (100 mg/kg) |
| plasma | tumor | plasma | tumor |
| C0 (μg/mL) | 503 | | | |
| Kel (h-1) | 0.93 | 0.06 | 0.2 | 0.1 |
| T1/2 (h) | 0.75 | 12.1 | 3.53 | 7.27 |
| Tmax (h) | | 0.58 | 12 | 12 |
| Cmax (ng/mL or ng/g) | | 488 | 144 | 5728 |
| AUC0-24 h (ng x h/ml or ng x h/g) | 331 | 6408 | 2182 | 88,600 |
| F% | | | 16.5% | 34.6% |
Eight-week-old female Balb/c mice ( CT26 tumor mode), 2.5 mg/kg, i.v.(2.5 mg/mL Senexin C solution in 5% dextrose); 100 mg/kg, p.o.(10 mg/mL Senexin C solution in 30% propylene glycol/70% PEG-400 vehicle)
[1].
| Animal Model: | eight-week-old female Balb/c mice ( CT26 tumor mode)[1] |
| Dosage: | 2.5 mg/kg (10 mL/kg of 2.5 mg/mL Senexin C solution in 5% dextrose), 100 mg/kg (10 mL/kg of 10 mg/mL Senexin C solution in 30% propylene glycol/70% PEG-400 vehicle) |
| Administration: | 2.5 mg/kg, i.v.; 100 mg/kg, p.o. |
| Result: | Showed good oral bioavailability. |
| Animal Model: | eight-week-old female NSG mice ( AML model)[1] |
| Dosage: | 40 mg/kg |
| Administration: | p.o.; twice daily, 4 weeks |
| Result: | Suppressed the systemic growth of MV4-11 AML with good tolerability. |
